The real gold standard for science, and academic freedom, requires upholding scientific work that investigates who and what ...

We aim to provide transparency in how Elevance Health plans address variations in clinical practices to ensure safe, ...

The 340B rebate pilot model set to begin in January 2026 starkly presents the key tradeoff between program integrity and ...

When the sole manufacturer withdrew a critical cancer drug from Medicare and Medicaid, patients were left without options.

The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...

In late August 2025, CMS released Performance Year (PY) 2024 data for the Medicare Shared Savings Program (MSSP). This marked ...

Margolis Center for Health Policy to the pod to discuss her recent Forefront article focused on how ACO REACH enabled ACOs to ...

Data fragmentation and inefficiency are most evident in the quality reporting approach currently used for accountable care organizations by the Centers for Medicare and Medicaid Services—the ...

Join Health Affairs on December 11 for a virtual event examining private equity’s impact on the practice of medicine.

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

Taylor holds a bachelor’s degree from the University of Washington (UW) School of Engineering in technical communication and a master’s degree in clinical informatics and patient-centered technology ...

Audrey Ford, MS, is a Policy Research Associate on the Health Care Transformation team at Duke-Margolis and supports projects on the Medicare accountable care portfol ...